References
- Health: OECD data [online database]. Paris: OECD Publishing; 2014, (http://data.oecd.org/health.htm, Accessed 10 August 2015)
- GodmanB, WettermarkB, HoffmannM, AnderssonK, HaycoxA, GustafssonL: Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009, 9(1):65–83.
- Pathways to value: pharma in a changing world. Oxford: Meteos; 2013, (PharmaFutures Global Conclusions, No. 5; http://apps.who.int/medicinedocs/en/d/Js20202en/, Accessed 10 August 2015)
- ShawJ, SicreeR, ZimmetP: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87(1):4–14.
- AbboudC, BermanE, CohenA, CortesJ, De AngeloD, DeiningerMet al: The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013, 121(22):4439–4442.
- KaiserJ: Personalized medicine: new cystic fibrosis drug offers hope, at a price. Science 2012, 335(6069):645.
- WHO Europe: ‘Access to new medicines in Europe: technical review of policy initiatives and opportunities for research’ 2015 WHO: Copenhagen http://www.euro.who.int/en/health-topics/Health-systems/medicines/publications2/2015/access-to-new-medicines-in-europe-technical-review-of-policy-initiatives-and-opportunities-for-collaboration-and-research available at:
- KellyR, SmithT. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol 2014, 15(3):e112–e118.
- Sofosbuvir 400mg tablet (Sovaldi®). SMC advice [website]. Glasgow: Scottish Medicines Consortium; 2014 [http://www.scottishmedicines.org.uk/SMC_Advice/Advice/964_14_sofosbuvir_Sovaldi/sofosbuvir_Sovaldi]
- MalmströmR, GodmanB, DiogeneE, BaumgärtelC, BennieM, BishopI, et al: Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol 2013, 4:39.
- CohenP, FelixA: Are payers treating orphan drugs differently? Journal of Market Access & Health Policy 2014, 2:23513.
- MichelM, ToumiM: Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res 2012, 12(1):23–29.
- WettermarkB, GodmanB, ErikssonC, van GanseE, GarattiniS, JoppiRet al: Einführung neuer Arzneimittel in europäische Gesundheitssysteme [Introduction of new medicines into European healthcare systems]. GGW 2010, 10(3):24–34
- GodmanB, MalmströmR, DiogeneE, GrayA, JayathissaS, TimoneyAet al: Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol 2015, 8(1):77–94.